^
    Back
    Association details:
    Biomarker:BRAF V600E
    Cancer:Colorectal Cancer
    Drug:JSI-1187 (ERK2 inhibitor, ERK1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    AACR-II 2020
    Title:

    Abstract 4188: The ERK1/2 inhibitor, JSI-1187, demonstrates preclinical efficacy in tumor models with MAPK pathway mutations

    Published date:
    05/15/2020
    Excerpt:
    In anti-proliferation assays, JSI-1187 had IC50 of 37 NM in the BRAF V600E melanonma cell line A375 and 48 NM in the BRAF V600E CRC cell line COLO 205.
    DOI:
    10.1158/1538-7445.AM2020-4188